Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» atypical hemolytic uremic syndrome
atypical hemolytic uremic syndrome
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Yahoo/BusinessWire
Soliris
atypical hemolytic uremic syndrome
Alexion
Flag link:
Alexion's Soliris receives marketing approval in Japan
Alexion's Soliris receives marketing approval in Japan
The Fly on the Wall
Japan
Soliris
Alexion
atypical hemolytic uremic syndrome
Flag link:
Alexion Pharma on a High
Alexion Pharma on a High
Yahoo/Zacks.com
Alexion
Soliris
aHUS
atypical hemolytic uremic syndrome
Flag link:
Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS
Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS
Benzinga
Soliris
Alexion
atypical hemolytic uremic syndrome
Flag link:
Positive Data on Alexion's Soliris
Positive Data on Alexion's Soliris
Yahoo/Zacks.com
Soliris
Alexion
aHUS
atypical hemolytic uremic syndrome
Flag link:
